Z. Kyriakakis et al., CISPLATIN, IFOSFAMIDE, METHOTREXATE AND VINBLASTINE COMBINATION CHEMOTHERAPY FOR METASTATIC UROTHELIAL CANCER, The Journal of urology, 158(2), 1997, pp. 408-411
Purpose: We investigated the activity of combination chemotherapy cons
isting of cisplatin, ifosfamide, methotrexate and vinblastine in patie
nts with metastatic urothelial cancer. Materials and Methods: A total
of 32 consecutive patients was treated with 30 mg./m.(2) cisplatin on
days 1 through 3, 1.5 gm./m.(2) ifosfamide with mesna on days 1 throug
h 3, 30 mg./m.(2) methotrexate and 3 mg./m.(2) vinblastine on day 1 pl
us 5 mu g./kg. granulocyte colony-stimulating factor on days 7 through
11. Courses were repeated every 21 days for a maximum of 6 cycles. Re
sults: Major toxicity was granulocytopenia in 56% of patients, includi
ng 11 episodes of granulocytopenic fever. Anemia and thrombocytopenia
developed in a third of the cases. No other significant toxicity or tr
eatment related death was noted. An objective response was achieved in
20 patients (62.5%, 95% confidence interval 44 to 79). Median time to
progression was 7 months and median survival was 13 months. Conclusio
ns: The cisplatin, ifosfamide, methotrexate and vinblastine regimen ap
peared active in patients with metastatic urothelial carcinoma. This r
egimen was associated with significant but manageable hematological to
xicity and the incidence of mucositis or renal impairment was low. Pro
spective randomized studies are needed to assess whether the addition
of ifosfamide to other active agents will improve the survival of pati
ents with this disease.